S'abonner

HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR SEVERE COMBINED IMMUNODEFICIENCY DISEASE - 04/09/11

Doi : 10.1016/S0889-8561(05)70142-9 
Trudy Small, MD *

Résumé

Severe combined immunodeficiency disease (SCID) refers to a heterogeneous group of rare (1/100,000 live births), lethal, congenital disorders that result in the inability of T cells to respond to mitogens, alloantigens, and specific antigens and B cells to produce specific antibodies.1 Before the early 1990s, patients with this disorder were characterized primarily by the phenotype and function of their circulating lymphocytes, mode of inheritance, and presence or absence of enzyme deficiencies known to be associated with SCID, such as adenosine deaminase. In this original classification, three main types of SCID were described2 and include the following: (1) classical SCID, characterized by T and B lymphopenia, with or without natural killer (NK) cells, and agammaglobulinemia, (2) the more common SCID with B lymphocytes, and (3) SCID secondary to adenosine deaminase (ADA) deficiency, which may present with either of the preceding lymphoid phenotypes.3, 4 Less often, children with SCID present with Omenn's syndrome,5 in which affected infants have scaling erythroderma, leukocytosis, eosinophilia, hepatosplenomegaly, and lymphadenopathy with replacement of nodal architecture by Langerhans and reticulum cells,6 reticular dysgenesis,7 in which SCID is associated with severe neutropenia and often bilateral sensorineural deafness,8 or SCID with short-limbed dwarfism and ectodermal dysplasia.9 Multiple variants of SCID have been described in which patients have nonfunctional T cells that demonstrate capping defects,10 lack CD711 or possess abnormal CD3 subunit expression,12 or have CD8 deficiency with nonfunctional CD4+ cells.13, 14 Despite this phenotypic heterogeneity, the distribution of SCID phenotypes reported in four separate studies performed in Europe and the United States was surprisingly similar.15, 16, 17, 18 Approximately 40% of patients presented as SCID with B cells, 25% as classical SCIDs (BT), 15% with ADA deficiency, 10% as SCIDs with nonfunctional T cells, and 2% to 3% with reticular dysgenesis. Inheritance of these disorders are either autosomal recessive (ADA deficiency,4, 19 short-limbed dwarfism,9 Omenn's syndrome,5 capping defects,10 CD8 deficiency,13, 14 or as either an X-linked or autosomal recessive disorder (classical SCID, SCID with B cells, reticular dysgenesis).14, 20

Although first trimester diagnosis of adenosine deaminase deficiency has been possible for many years by measurement of enzyme activity in cultured amniocytes or chorionic villi samples,21 children with ADA+ SCID, until recently, required fetal blood sampling to ascertain the presence or absence of T cells.22 The elucidation of many of the genetic mutations which give rise to SCID, such as X-linked SCID (IL-2R gamma chain),23, 24, 25 autosomal recessive SCID with B cells (JAK-3),26, 27 classic SCID, Omenn's syndrome28, 29, 30, 31 (recombinase defects (RAG-1, RAG-2), and CD8 deficiency with nonfunctional T-cells (ZAP-70),32, 33, 34 has increased the proportion of infants who can be diagnosed by amniocentesis or chorionic villus sampling (CVS).35, 36 Better prenatal diagnosis, earlier postnatal diagnosis, because of heightened awareness of immunodeficiency disorders resulting from the AIDS epidemic, in conjunction with advances in anti-microbial therapy, have reduced the number of children presenting to bone marrow transplant (BMT) with a life-threatening infection.

Successful correction of SCID by BMT was first reported by Gatti et al using bone marrow derived from an HLA-matched sibling.37 Since that report, over 500 curative transplants for this disorder have been performed,38 the majority using T-cell–depleted haploidentical parental bone marrow. Within the last 5 years, advances in unrelated bone marrow39 and cord blood transplantation40 and successes with in utero stem cell transplants41 have expanded the options available to infants with SCID, particularly those lacking an HLA-matched sibling. In this article, the results and continued controversies of stem cell transplantation for SCID are reviewed.

Le texte complet de cet article est disponible en PDF.

Plan


 Address reprint requests to Trudy Small, MD, Bone Marrow Transplant Service, Department of Pediatrics, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, Room H-1406, New York, NY 10021, e-mail: Small_Trudy_N/mskcc_PED@mskmail.mskcc.org


© 2000  W. B. Saunders Company. Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 20 - N° 1

P. 207-220 - février 2000 Retour au numéro
Article précédent Article précédent
  • ATAXIA-TELANGIECTASIA : A Primary Immunodeficiency Revisited
  • José R. Regueiro, Oscar Porras, Martin Lavin, Richard A. Gatti
| Article suivant Article suivant
  • GENE THERAPY FOR T-CELL IMMUNODEFICIENCIES
  • Donald B. Kohn, Kenneth I. Weinberg, Robertson Parkman

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2025 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.